Protein Variants | Comment | Organism |
---|---|---|
additional information | enzyme downregulation by specific AR-targeted siRNA transfection | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
Alrestatin | inhibits aldose reductase, does not appear to affect RUNX2 activation in cells exposed to euglycemia | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
bone marrow | bone marrow endothelial, HBME, cells | Homo sapiens | - |
endothelial cell | - |
Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
aldose reductase | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
additional information | inverse relationship between RUNX2 activity and AR expression, which is induced by hyperglycemia and supports a role for AR in the suppression of RUNX2 activity under hyperglycemic conditions | Homo sapiens |
physiological function | the aldose reductase polyol pathway contributes to microvascular complications since the enzyme mediates vascular damage in response to hyperglycemia. Inhibition of AR reverses hyperglycemic suppression of RUNX2, and it also negatively regulates RUNX2-dependent vascular remodeling in an endothelial cell wounded monolayer assay, which is reversed by specific AR inhibition in hyperglycemia. RUNX2 and aldose reductase regulate glucose-activated endothelial cell wound healing | Homo sapiens |